Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
Hemab has raised $157.0M in total funding. The most recent round was Series C. The last funding was announced in October 2025.
Hemab's investors include RA Capital Management, Sofinnova Partners, Novo Holdings, Invus, Rock Springs Capital.
Hemab is headquartered in Copenhagen, Denmark.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
Hemab is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hemab — Funding & Investors." VCBacked, October 27, 2025, https://www.vcbacked.co/company/hemab. Accessed July 19, 2026.
VCBacked. (2025). Hemab — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/hemab
{{cite web |title=Hemab — Funding & Investors |url=https://www.vcbacked.co/company/hemab |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated